Cabaletta Bio, Inc

(NASDAQ:CABA)

Latest On Cabaletta Bio, Inc (CABA):

Date/Time Type Description Signal Details
2023-05-18 16:00 ESTNewsCabaletta Bio up 1%, prices $87M offeringN/A
2023-05-18 02:29 ESTNewsCabaletta Bio commences underwritten public offering of sharesN/A
2023-05-16 23:33 ESTNewsCabaletta Bio jumps 16% as FDA clears trial for myositis candidateN/A
2023-05-11 15:27 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.02N/A
2023-05-01 18:20 ESTNewsCabaletta's potential lupus drug CABA-201 gets FDA fast track tagN/A
2023-04-28 03:16 ESTNewsCabaletta Bio: Speculative Biotech With OpportunityN/A
2023-03-31 16:02 ESTNewsCabaletta CAR T cell therapy for lupus gets FDA nod to enter trialN/A
2023-03-31 16:02 ESTNews4 stocks to watch on Friday: Amazon, Kraft Heinz, and moreN/A
2023-03-16 13:19 ESTNewsCabaletta Bio GAAP EPS of -$0.52 misses by $0.08N/A
2023-01-27 17:59 ESTNewsCabaletta rises as Morgan Stanley upgrades citing new CAR-T assetN/A
2023-01-25 12:46 ESTNewsCabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)N/A
2022-12-08 20:30 ESTNewsCabaletta Bio dips on announcing $35M offeringN/A
2022-11-10 11:40 ESTNewsCabaletta Bio GAAP EPS of -$0.39 beats by $0.09N/A
2022-08-30 16:03 ESTNewsCabaletta downgraded at Morgan Stanley on upcoming data for lead assetN/A
2022-08-11 21:46 ESTNewsCabaletta Bio GAAP EPS of -$0.45 beats by $0.05N/A
2022-05-18 20:14 ESTNewsCabaletta Bio updates Phase 1 interim data for lead assetN/A
2022-05-12 11:04 ESTNewsCabaletta Bio GAAP EPS of -$0.45N/A
2022-03-18 09:46 ESTNewsCabaletta Bio GAAP EPS of -$0.49 beats by $0.11N/A
2021-12-14 08:41 ESTNewsCabaletta Bio tanks 34% on cell therapy data in early-stage study for pemphigus vulgarisN/A
2021-11-01 14:01 ESTNewsCabaletta Bio EPS beats by $0.05N/A
2021-11-01 14:01 ESTNewsCabaletta rises as skin diseases drug shown to be safe in early data of phase 1 trialN/A
2021-08-19 00:00 ESTNewsCabaletta Bio reports results from DesCAARTes trial in patients with pemphigus vulgarisN/A
2021-08-05 20:25 ESTNewsCabaletta Bio EPS beats by $0.03N/A
2021-03-18 15:25 ESTAnalyst RatingThe Analyst Target Price has increased from $20.33 to $22.25.Buy
2021-03-18 07:46 ESTFinancialsCompany financials have been released.Neutral
2021-03-17 17:01 ESTNewsCabaletta Bio EPS misses by $0.04N/A
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$0.46 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 15:39 ESTEarnings EstimateAn EPS average of -$2.18 is estimated for the 2022 year.Sell
2021-01-20 12:58 ESTNewsCabaletta: DSG3-CAART's 1H 2021 Data Release Can Substantiate This Young BiotechN/A
2021-01-11 10:22 ESTAnalyst RatingThe Analyst Target Price has increased from $20 to $20.33.Buy
2021-01-09 03:37 ESTNewsChardan Capital initiates Cabaletta Bio with Buy ratingN/A
2020-12-10 06:47 ESTNewsDosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorderN/A
2020-12-04 06:26 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 00:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 15:51 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.67 to $20.Neutral
2020-11-17 07:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 23:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 07:15 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 09:52 ESTNewsCabaletta Bio EPS beats by $0.08N/A
2020-11-11 09:52 ESTNewsCabaletta Bio +5% on Q3 results, pipeline updateN/A
2020-11-11 06:54 ESTEarnings EstimateAn EPS average of -$0.44 is estimated for the quarter ending on March 31, 2021.Sell
2020-10-15 08:02 ESTNewsCabaletta Bio (CABA) Investor Presentation - SlideshowN/A
2020-10-14 11:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $22.5 to $21.67.Neutral
2020-10-08 21:07 ESTFinancialsCompany financials have been released.Neutral
2020-10-04 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 09:18 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 12:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 03:29 ESTFinancialsCompany financials have been released.Neutral
2020-08-07 23:40 ESTFinancialsCompany financials have been released.Neutral

About Cabaletta Bio, Inc (CABA):

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.

See Advanced Chart

General

  • Name Cabaletta Bio, Inc
  • Symbol CABA
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 31
  • Fiscal Year EndDecember
  • IPO Date2019-10-25
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.cabalettabio.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 2.23
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.13
  • Next Year EPS Estimate -$2.45
  • Next Quarter EPS Estimate -$0.42
  • Return on Assets -17%
  • Return on Equity -27%
  • Earnings Per Share -$0.94
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 276.24 million
  • Analyst Target Price $22.25
View More

Share Statistics

  • Shares Outstanding 24.06 million
  • Shares Float 7.91 million
  • % Held by Insiders 523%
  • % Held by Institutions 67.4%
  • Shares Short 1.63 million
  • Shares Short Prior Month 1.61 million
  • Short Ratio 15.52
  • Short % of Float 8%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $16.38
  • 52 Week Low $6.07
  • 50 Day Moving Average 11.96
  • 200 Day Moving Average 12.4
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cabaletta Bio, Inc (CABA) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cabaletta Bio, Inc (CABA) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-16$N/A-$0.40-$0.36-11.11%
2020-09-302020-11-10$N/A-$0.36-$0.4418.18%
2020-06-302020-08-06$N/A-$0.35-$0.3910.26%
2020-03-312020-05-12$N/A-$0.33-$0.23-43.48%
2019-12-312020-03-30$N/A-$0.33-$0.4729.79%
2019-09-302019-12-05$N/A-$1.21-$2.2646.46%

Cabaletta Bio, Inc (CABA) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 5.78 million N/A N/A 4.62 million 3.03 million
Income Before Tax -9.31 million N/A N/A -7.49 million -5.4 million
Selling General Administrative 3.56 million N/A N/A 3.28 million 2.83 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -9.22 million N/A N/A -7.82 million -5.81 million
Operating Income -9.33 million N/A N/A -7.9 million -5.86 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A N/A
Net Income From Continuing Operations -9.31 million N/A N/A -7.49 million -5.4 million
Net Income Applicable to Common Shares -9.31 million -8.39 million -8.15 million N/A -5.4 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments 1.47 million N/A -226000 -273000 -40000
Change to Liabilities N/A -978000 N/A -306000 672000
Total Cash Flow from Investing Activities N/A -11.12 million N/A -273000 -40000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 135000 N/A -44000 73.32 million -2.1 million
Change to Operating Activities N/A 315000 N/A -3.04 million 1.3 million
Change in Cash -3.42 million N/A -5.2 million 65.16 million -4.22 million
Total Cash from Operating Activities -5.02 million -7.64 million -4.93 million -7.88 million -2.08 million
Depreciation 90000 N/A 76000 51000 32000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -147000 N/A 2.1 million -2.1 million
Change to Net Income N/A 1.1 million N/A 819000 569000
Capital Expenditures 162000 N/A 226000 273000 40000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Total Stockholder Equity 109.54 million 117.51 million N/A 131.71 million 138.32 million
Other Current Liabilities 38000 140000 N/A 101000 177000
Total Assets 114.72 million 121.77 million N/A 134.97 million 141.47 million
Common Stock N/A N/A N/A N/A N/A
Other Current Assets 1.85 million N/A N/A N/A N/A
Retained Earnings -66.3 million -56.99 million -48.6 million -40.44 million -32.96 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 299000 N/A 238000 N/A 101000
Cash 101.43 million 108.68 million N/A 131 million 136.2 million
Total Current Liabilities 5.18 million 4.27 million N/A 3.26 million 3.15 million
Other Stockholder Equity 6000 N/A 11000 N/A N/A
Property, Plant & Equipment 890000 N/A 806000 N/A 815000
Total Current Assets 113.54 million 119.22 million N/A 134.12 million 140.55 million
Long Term Investments N/A 1.33 million N/A N/A N/A
Net Tangible Assets 109.54 million N/A 124.64 million N/A 138.32 million
Short Term Investments 7.23 million 8.06 million N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.24 million 953000 N/A 1.99 million 920000

Cabaletta Bio, Inc (CABA) Chart:

Cabaletta Bio, Inc (CABA) News:

Below you will find a list of latest news for Cabaletta Bio, Inc (CABA) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cabaletta Bio, Inc (CABA) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-170.50CALL0 00TRUE00
2026-07-1710CALL0 00TRUE00
2026-07-171.50CALL0 330TRUE00
2026-07-1720CALL0 310TRUE00
2026-07-172.51CALL9 72260.59TRUE0.40.67
2026-07-1730.3CALL108 138174.82TRUE0.10.5
2026-07-173.50.15CALL38 89070.29FALSE0.050.5
2026-07-1740.05CALL200 109282.78FALSE0.050
2026-07-174.50CALL0 49289.07FALSE00
2026-07-1750CALL0 322374.58FALSE00
2026-07-175.50CALL0 17405.07FALSE00
2026-07-177.50CALL0 13223.39FALSE00
2026-07-170.50PUT0 6854.38FALSE00
2026-07-1710PUT0 4347.86FALSE00
2026-07-171.50PUT0 2236.09FALSE00
2026-07-1720PUT0 3157.13FALSE00
2026-07-172.50.05PUT1 13115.42FALSE0.050
2026-07-1730.15PUT6 20883.18FALSE-0.07-0.32
2026-07-173.50PUT0 27555.53TRUE00
2026-07-1740.8PUT10 131112.7TRUE0.80
2026-07-174.50PUT0 0129.79TRUE00
2026-07-1750PUT0 0156.86TRUE00
2026-07-175.50PUT0 0180.2TRUE00
2026-07-177.50PUT0 00TRUE00
2026-08-210.50CALL0 36243.12TRUE00
2026-08-2110CALL0 200TRUE00
2026-08-211.50CALL0 450TRUE00
2026-08-2121.1CALL0 580TRUE00
2026-08-212.50.85CALL5 3766897.75TRUE0.850
2026-08-2130.55CALL42 1000997.03TRUE0.10.22
2026-08-213.50.28CALL15 93077.11FALSE0.030.12
2026-08-2140.25CALL42 37982.96FALSE0.060.32
2026-08-214.50CALL0 48104.09FALSE00
2026-08-2150.1CALL27 68797.58FALSE0.10
2026-08-215.50CALL0 10221.25FALSE00
2026-08-217.50CALL0 920270.62FALSE00
2026-08-210.50PUT0 9301.63FALSE00
2026-08-2110.05PUT0 2329.02FALSE00
2026-08-211.50PUT0 5129.81FALSE00
2026-08-2120PUT0 2103.4FALSE00
2026-08-212.50.15PUT0 377106.06FALSE00
2026-08-2130PUT0 11098.01FALSE00
2026-08-213.50PUT0 0110.36TRUE00
2026-08-2140PUT0 45108.22TRUE00
2026-08-214.50PUT0 10154.11TRUE00
2026-08-2150PUT0 1990.39TRUE00
2026-08-215.50PUT0 0139.32TRUE00
2026-08-217.50PUT0 0167.54TRUE00
2026-09-180.52.72CALL42 72188.87TRUE2.720
2026-09-1810CALL0 36279.63TRUE00
2026-09-181.50CALL0 1250TRUE00
2026-09-1820CALL0 55980.42TRUE00
2026-09-182.50.9CALL0 6772117.77TRUE00
2026-09-1830.63CALL10 3638104.27TRUE0.630
2026-09-183.50.45CALL0 39274.01FALSE00
2026-09-1840.4CALL6 161106.95FALSE0.10.33
2026-09-184.50CALL0 61156.13FALSE00
2026-09-1850.16CALL0 332171.98FALSE00
2026-09-185.50.4CALL0 38154.37FALSE00
2026-09-187.50.05CALL2 972211.79FALSE0.050
2026-09-180.50PUT0 15317.49FALSE00
2026-09-1810PUT0 0446.94FALSE00
2026-09-181.50.2PUT0 2122.76FALSE00
2026-09-1820PUT0 0219.83FALSE00
2026-09-182.50.2PUT1 41169.03FALSE0.20
2026-09-1830PUT0 48115.65FALSE00
2026-09-183.50PUT0 7123.4TRUE00
2026-09-1840PUT0 35114.22TRUE00
2026-09-184.50PUT0 1115.78TRUE00
2026-09-1850PUT0 8140.66TRUE00
2026-09-185.50PUT0 0124.75TRUE00
2026-09-187.50PUT0 0163.35TRUE00
2026-11-200.52.65CALL0 470TRUE00
2026-11-2012.3CALL1 16216.91TRUE2.30
2026-11-201.51.85CALL5 0125.67TRUE1.850
2026-11-2020CALL0 26109.17TRUE00
2026-11-202.50CALL0 37698.54TRUE00
2026-11-2030CALL0 41125.06TRUE00
2026-11-203.50.85CALL3 46118FALSE0.150.21
2026-11-2040.65CALL10 64123.18FALSE00
2026-11-204.50.5CALL6 999.37FALSE0.50
2026-11-2050.48CALL0 34120.81FALSE00
2026-11-205.50CALL0 917130.82FALSE00
2026-11-207.50CALL0 0160.34FALSE00
2026-11-200.50PUT0 100FALSE00
2026-11-2010PUT0 0334.04FALSE00
2026-11-201.50PUT0 1227.44FALSE00
2026-11-2020PUT0 1164.64FALSE00
2026-11-202.50PUT0 245118.7FALSE00
2026-11-2030PUT0 10101FALSE00
2026-11-203.50PUT0 0125.69TRUE00
2026-11-2040PUT0 0112.18TRUE00
2026-11-204.50PUT0 20120.79TRUE00
2026-11-2050PUT0 0107.11TRUE00
2026-11-205.50PUT0 0137.4TRUE00
2026-11-207.50PUT0 0125.69TRUE00
2027-01-150.52.69CALL31 330TRUE0.090.03
2027-01-1512.3CALL1 32208.56TRUE0.10.05
2027-01-151.51.95CALL50 234148.42TRUE0.150.08
2027-01-1521.6CALL0 134175.06TRUE00
2027-01-152.50CALL0 555131.23TRUE00
2027-01-1531.25CALL16 1140135.81TRUE0.250.25
2027-01-153.51.1CALL13 517115.87FALSE1.10
2027-01-1540.75CALL26 184108.93FALSE-0.05-0.06
2027-01-154.50.75CALL6 31118.43FALSE0.750
2027-01-1550.58CALL26 1861120.5FALSE0.030.05
2027-01-155.50.4CALL0 165110.14FALSE00
2027-01-157.50.3CALL14 10120.57FALSE0.30
2027-01-150.50PUT0 90FALSE00
2027-01-1510PUT0 0283.97FALSE00
2027-01-151.50PUT0 12193.46FALSE00
2027-01-1520PUT0 256179.93FALSE00
2027-01-152.50PUT0 265122.26FALSE00
2027-01-1530PUT0 16131.93FALSE00
2027-01-153.50PUT0 60142.1TRUE00
2027-01-1540PUT0 50134.53TRUE00
2027-01-154.50PUT0 2120.03TRUE00
2027-01-1552.4PUT19 19120.04TRUE2.40
2027-01-155.50PUT0 50118.41TRUE00
2027-01-157.50PUT0 200109.51TRUE00
2027-02-190.52.75CALL3 44164.51TRUE0.150.06
2027-02-191.50CALL0 095.22TRUE00
2027-02-1920CALL0 0116.13TRUE00
2027-02-192.50CALL0 10113.89TRUE00
2027-02-1931.2CALL16 120124.72TRUE00
2027-02-193.50CALL0 0114.27FALSE00
2027-02-1940CALL0 0107.51FALSE00
2027-02-194.50CALL0 0113.74FALSE00
2027-02-1950.7CALL32 0115.66FALSE0.70
2027-02-195.50.5CALL13 5123.62FALSE-0.1-0.17
2027-02-190.50PUT0 00FALSE00
2027-02-191.50PUT0 0178.83FALSE00
2027-02-1920PUT0 0129.73FALSE00
2027-02-192.50PUT0 0113.21FALSE00
2027-02-1931PUT3 0133.94FALSE10
2027-02-193.50PUT0 0131.72TRUE00
2027-02-1940PUT0 0119.7TRUE00
2027-02-194.50PUT0 0116.5TRUE00
2027-02-1950PUT0 0121.55TRUE00
2027-02-195.50PUT0 0120.26TRUE00
2028-01-210.52.88CALL42 233167.89TRUE0.230.09
2028-01-2112.65CALL15 39162.47TRUE2.650
2028-01-211.52.4CALL0 99129.52TRUE00
2028-01-2122.1CALL1 413137.18TRUE0.050.02
2028-01-212.51.91CALL4 398112.07TRUE-0.43-0.18
2028-01-2132.5CALL9 561145.7TRUE0.670.37
2028-01-213.51.71CALL5 137144.63FALSE0.010.01
2028-01-2142CALL4 258161.09FALSE0.40.25
2028-01-214.50CALL0 13117.58FALSE00
2028-01-2151.65CALL10 195136.15FALSE0.290.21
2028-01-215.51.35CALL20 270131.63FALSE-0.04-0.03
2028-01-210.50PUT0 11175.14FALSE00
2028-01-2110PUT0 0172.27FALSE00
2028-01-211.50PUT0 0172.48FALSE00
2028-01-2120PUT0 20148.58FALSE00
2028-01-212.50PUT0 4490.84FALSE00
2028-01-2131.55PUT0 809139.08FALSE00
2028-01-213.50PUT0 38135.91TRUE00
2028-01-2140PUT0 20136.32TRUE00
2028-01-214.50PUT0 15124.5TRUE00
2028-01-2153.2PUT40 85131.26TRUE3.20
2028-01-215.50PUT0 2129.98TRUE00

Latest CABA Trades:

Date Shares Price
Jun 13, 2022 7:37 PM EST1$1.08
Jun 13, 2022 7:37 PM EST6$1.08
Jun 13, 2022 7:51 PM EST7$1.06
Jun 13, 2022 7:57 PM EST7$1.06
Jun 13, 2022 7:58 PM EST7$1.055

Cabaletta Bio, Inc (CABA) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025941/0000899243-19-025941-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025942/0000899243-19-025942-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025943/0000899243-19-025943-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025946/0000899243-19-025946-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319025947/0000899243-19-025947-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026016/0000899243-19-026016-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026017/0000899243-19-026017-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026018/0000899243-19-026018-index.htm
2019-10-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026020/0000899243-19-026020-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026345/0000899243-19-026345-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924319026346/0000899243-19-026346-index.htm
2020-02-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004509/0000899243-20-004509-index.htm
2020-02-135Annual statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320004511/0000899243-20-004511-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006864/0000899243-20-006864-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006865/0000899243-20-006865-index.htm
2020-03-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320006867/0000899243-20-006867-index.htm
2020-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000089924320025326/0000899243-20-025326-index.htm
2020-07-21SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000090266420002724/0000902664-20-002724-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963819000988/0000929638-19-000988-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000092963820000331/0000929638-20-000331-index.htm
2019-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919056233/0001104659-19-056233-index.htm
2019-10-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919057348/0001104659-19-057348-index.htm
2019-10-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-11-12SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1759138/000110465919061822/0001104659-19-061822-index.htm
2019-10-24S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519273939/0001193125-19-273939-index.htm
2019-10-25424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1759138/000119312519274807/0001193125-19-274807-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519277804/0001193125-19-277804-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312519278927/0001193125-19-278927-index.htm
2019-11-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312519287367/0001193125-19-287367-index.htm
2020-01-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520005110/0001193125-20-005110-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520017724/0001193125-20-017724-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520038349/0001193125-20-038349-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520042689/0001193125-20-042689-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520090013/0001193125-20-090013-index.htm
2020-03-30S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520091086/0001193125-20-091086-index.htm
2020-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1759138/000119312520115863/0001193125-20-115863-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520134391/0001193125-20-134391-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520139782/0001193125-20-139782-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520153792/0001193125-20-153792-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520159049/0001193125-20-159049-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1759138/000119312520211336/0001193125-20-211336-index.htm
2019-10-30SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001374/0001193805-19-001374-index.htm
2019-10-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1759138/000119380520000185/0001193805-20-000185-index.htm
2019-12-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459019045375/0001564590-19-045375-index.htm
2020-03-3010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1759138/000156459020013929/0001564590-20-013929-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020024508/0001564590-20-024508-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1759138/000156459020037278/0001564590-20-037278-index.htm
2019-10-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1759138/999999999519002384/9999999995-19-002384-index.htm

Cabaletta Bio, Inc (CABA) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cabaletta Bio, Inc (CABA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 523%
Institutional Ownership: 6740%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-10-295AM Ventures V, L.P.10% Share HolderBuy454,545.0011.004,999,995.00454,545.00https://www.sec.gov/Archives/edgar/data/1759138/000110465919058504/0001104659-19-058504-index.htm
2019-10-29James E Flynn10% Share HolderBuy700,000.0011.007,700,000.00700,000.00https://www.sec.gov/Archives/edgar/data/1759138/000119380519001376/0001193805-19-001376-index.htm